首页 | 本学科首页   官方微博 | 高级检索  
     

促红细胞生成素联用参附注射液治疗慢性心力衰竭的疗效观察
引用本文:吴锦波,王志兵,袁诚. 促红细胞生成素联用参附注射液治疗慢性心力衰竭的疗效观察[J]. 中国循证心血管医学杂志, 2013, 0(3): 244-246
作者姓名:吴锦波  王志兵  袁诚
作者单位:东莞市虎门中医院,东莞441900
基金项目:东莞市科技局项目(201110515029140)
摘    要:目的 观察促红细胞生成素(erythropoietin,EPO)联合参附注射液治疗慢性心力衰竭(chronic heart failure,CHF)的临床疗效.方法 将160例CHF患者随机分成对照组(n=40)、EPO组(n=40)、参附注射液组(参附组,n=40)和EPO联合参附注射液组(EPO+参附组,n=40),比较治疗前后各组患者的心功能分级(NYHA)和明尼苏达心力衰竭生活质量评分、左心室射血分数(left ventricular ejection fraction,LVEF)、左心室舒张末期内径(left ventricular end-diastolic diameter,LVEDD)、血浆N末端脑钠肽前体(NT-proBNP)水平、再住院率,不良反应发生情况.结果 治疗后4组心功能均得到了提高,以EPO+参附组改善最为明显,心功能评级由(3.7±0.47)降至(1.2±0.52),生活质量评分由(46.5±1.41)降为(22.1±2.53),同时NT-proBNP水平均也由治疗前(2712.2±323.30)ng/L降至(352.0±60.52)ng/L,LVEF由(31.3±2.88)%升至(48.1±5.21)%,LVEDD由(67.1±2.35)mm降至(52.1±3.33)mm,再入院率为35.0%,均低于其他三组.结论 EPO联合参附注射液治疗慢性心力衰竭能明显改善心功能、提高生活质量和降低再住院率,显著提高临床疗效.

关 键 词:慢性心力衰竭  促红细胞生成素  参附注射液

Treatment of chronic heart failure with erythropoietin combining Shenfu Injection
WU Jin-bo,WANG Zhi-bing,YUAN cheng. Treatment of chronic heart failure with erythropoietin combining Shenfu Injection[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2013, 0(3): 244-246
Authors:WU Jin-bo  WANG Zhi-bing  YUAN cheng
Affiliation:(Humen Hospital of Chinese Medicine, Dongguan, 523938 China.)
Abstract:Objective To observe the curative effect of erythropoietin (EPO) combining Shenfu Injection on chronic heart failure (CHF). Methods The patients with CHF (n=160) were randomly divided into control group (routine treatment), EPO group, Shenfu Injection group and EPO combining Shenfu Injection group (combining group, each n=40). The scores of NYHA and Minnesota Heart Failure Quality of Life Scale, LVEF, LVEDD and NT-pro-BNP were recorded in all groups before and after treatment. The rate of re-hospitalization and adverse reactions were observed. Results The heart function was improved in all four groups and was more. significant in combining group. To EPO + Shenfu group improved most obviously, the degree of cardiac function decreased from (3.7 ±0.47) to (1.2 ± 0.52), quality of life scores decreased from the (46.5 ± 1.41) to (22.1 ± 2.53), while NT- proBNP levels were also decreased from (2712.2 ± 323.30)ng/L to (352.0 ± 60.52)ng/L, LVEF increased from (31.3 ± 2.88)% to (48.1 ± 5.21)%, LVEDD decreased from (67.1 ± 2.35) mm to (52.1 ± 3.33) mm., and the readmission was 35.0%, which was lower than other three groups. Conclusion EPO combining Shenfu Injection can significantly improve the heart function, promote the quality of life, reduce the rate of re-hospitalization, and enhance curative effect.
Keywords:Chronic heart failure  Erythropoietin  Shenfu Injection
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号